Feed Your Mind with New Materials on GMOs from FDA
SILVER SPRING, Md., Aug. 4, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration's (FDA) Feed Your Mind is an education initiative to help consumers learn about genetically engineered foods, commonly called GMOs. The Initiative was developed in collaboration with the U.S. Department of Agriculture (USDA) and the U.S. Environmental Protection Agency (EPA), to provide consumers with science-based information about how GMOs are made, what plants and animals are GMOs, the safety of GMOs, and how GMOs are regulated in the U.S.
Since the launch of the Feed Your Mind initiative in March 2020, the FDA has shared a wide range of resources including an agricultural biotechnology website, fact sheets, infographics, videos, and supplementary curricula for middle and high school classrooms. The Initiative is a multi-phased effort, and the most recent updates include new materials for consumers, health educators, and healthcare professionals to continue to educate, inform, and broaden understanding of GMOs.
As a part of this phase of the Initiative, the FDA also developed specialized materials for healthcare professionals.
Understanding GMOs: This online learning series, developed in collaboration with the Academy of Nutrition and Dietetics, is a free continuing professional education activity aimed to educate registered dietitians, registered dietitian nutritionists, and other healthcare professionals about agricultural biotechnology and GMOs. With help from four expert presenters, from the FDA, USDA, EPA, and U.S. Agency for International Development, this video provides useful information that can be shared with clients or patients who seek answers to questions about GMO foods. An accompanying fact sheet that reinforces the content covered in the Online Learning Series video will also be available.
Funding for Feed Your Mind was provided by Congress in 2017, 2018, and 2019.
The "KEYTRUDA Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering.
The report provides comprehensive insights about KEYTRUDA for ovarian cancer in the seven major markets. A detailed...
The "Peptide Synthesis Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Peptide Synthesis Method, Type of Chemical Synthesis, Contract Manufacturing Organization Size, Key Geographical Regions" report has been added to...
The "Laboratory Filtration Equipment - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
Global Laboratory Filtration Equipment Market to Reach $3 Billion by 2030
The global market for Laboratory...
The "Global Weight Loss Drugs Market: Analysis By Product Type, By Drug Type, By Distribution Channel, By End User, By Region, Size and Trends with Impact of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's...
Arrowhead Pharmaceuticals, Inc. today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company's proprietary Targeted RNAi Molecule...
Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share Related to Acquired IPR&D and...